• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发一种用于估计 SARS-CoV-2 关注变体的流行病学特征的模型推断系统。

Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern.

机构信息

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA.

出版信息

Nat Commun. 2021 Sep 22;12(1):5573. doi: 10.1038/s41467-021-25913-9.

DOI:10.1038/s41467-021-25913-9
PMID:34552095
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8458278/
Abstract

To support COVID-19 pandemic planning, we develop a model-inference system to estimate epidemiological properties of new SARS-CoV-2 variants of concern using case and mortality data while accounting for under-ascertainment, disease seasonality, non-pharmaceutical interventions, and mass-vaccination. Applying this system to study three variants of concern, we estimate that B.1.1.7 has a 46.6% (95% CI: 32.3-54.6%) transmissibility increase but nominal immune escape from protection induced by prior wild-type infection; B.1.351 has a 32.4% (95% CI: 14.6-48.0%) transmissibility increase and 61.3% (95% CI: 42.6-85.8%) immune escape; and P.1 has a 43.3% (95% CI: 30.3-65.3%) transmissibility increase and 52.5% (95% CI: 0-75.8%) immune escape. Model simulations indicate that B.1.351 and P.1 could outcompete B.1.1.7 and lead to increased infections. Our findings highlight the importance of preventing the spread of variants of concern, via continued preventive measures, prompt mass-vaccination, continued vaccine efficacy monitoring, and possible updating of vaccine formulations to ensure high efficacy.

摘要

为支持 COVID-19 大流行规划,我们开发了一个模型推断系统,使用病例和死亡率数据来估计新的 SARS-CoV-2 关注变异株的流行病学特性,同时考虑到未确定的病例、疾病季节性、非药物干预措施和大规模疫苗接种。应用该系统研究三种关注变异株,我们估计 B.1.1.7 的传播能力增加了 46.6%(95%CI:32.3-54.6%),但对先前野生型感染诱导的保护具有名义上的免疫逃逸;B.1.351 的传播能力增加了 32.4%(95%CI:14.6-48.0%),免疫逃逸能力增加了 61.3%(95%CI:42.6-85.8%);而 P.1 的传播能力增加了 43.3%(95%CI:30.3-65.3%),免疫逃逸能力增加了 52.5%(95%CI:0-75.8%)。模型模拟表明,B.1.351 和 P.1 可能会超过 B.1.1.7,导致感染增加。我们的研究结果强调了通过持续的预防措施、及时的大规模疫苗接种、持续的疫苗效力监测以及可能更新疫苗配方来防止关注变异株传播的重要性,以确保高疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/016e/8458278/21a5e4ab90be/41467_2021_25913_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/016e/8458278/4644530143c1/41467_2021_25913_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/016e/8458278/a60771d459bc/41467_2021_25913_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/016e/8458278/03b0f235137b/41467_2021_25913_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/016e/8458278/21a5e4ab90be/41467_2021_25913_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/016e/8458278/4644530143c1/41467_2021_25913_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/016e/8458278/a60771d459bc/41467_2021_25913_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/016e/8458278/03b0f235137b/41467_2021_25913_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/016e/8458278/21a5e4ab90be/41467_2021_25913_Fig4_HTML.jpg

相似文献

1
Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern.开发一种用于估计 SARS-CoV-2 关注变体的流行病学特征的模型推断系统。
Nat Commun. 2021 Sep 22;12(1):5573. doi: 10.1038/s41467-021-25913-9.
2
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.在 2020 年春季大流行期间估计 SARS-CoV-2 在纽约市的感染病死率:基于模型的分析。
Lancet Infect Dis. 2021 Feb;21(2):203-212. doi: 10.1016/S1473-3099(20)30769-6. Epub 2020 Oct 19.
3
COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.印度的新冠疫情动态、严重急性呼吸综合征冠状病毒2(SARS-CoV-2)德尔塔变异株及其对疫苗接种的影响
medRxiv. 2021 Nov 22:2021.06.21.21259268. doi: 10.1101/2021.06.21.21259268.
4
Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics.可能由具有不同特征的关注变体引发的 SARS-CoV-2 感染的未来波次。
Nat Commun. 2021 Sep 30;12(1):5730. doi: 10.1038/s41467-021-25915-7.
5
Coronavirus variants are spreading in India - what scientists know so far.新冠病毒变种正在印度传播——目前科学家所了解的情况。
Nature. 2021 May;593(7859):321-322. doi: 10.1038/d41586-021-01274-7.
6
Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape.具有增强传播性和/或部分免疫逃逸能力的 SARS-CoV-2 变异株对人群的影响。
Cell. 2021 Dec 22;184(26):6229-6242.e18. doi: 10.1016/j.cell.2021.11.026. Epub 2021 Nov 19.
7
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study.2019冠状病毒病的疫苗接种与非药物干预措施:一项数学建模研究
Lancet Infect Dis. 2021 Jun;21(6):793-802. doi: 10.1016/S1473-3099(21)00143-2. Epub 2021 Mar 18.
8
New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications.新型严重急性呼吸综合征冠状病毒2变体——对临床、公共卫生及疫苗的影响
N Engl J Med. 2021 May 13;384(19):1866-1868. doi: 10.1056/NEJMc2100362. Epub 2021 Mar 24.
9
Hotspots for SARS-CoV-2 Omicron variant spread: Lessons from New York City.新冠病毒奥密克戎变异株传播热点:来自纽约市的经验教训。
J Med Virol. 2022 Jul;94(7):2911-2914. doi: 10.1002/jmv.27691. Epub 2022 Mar 14.
10
Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study.新泽西州医护人员接种疫苗后的 SARS-COV-2 情况:一项基因组流行病学研究。
Microbiol Spectr. 2021 Dec 22;9(3):e0188221. doi: 10.1128/Spectrum.01882-21. Epub 2021 Nov 17.

引用本文的文献

1
Behavior-driven forecasts of neighborhood-level COVID-19 spread in New York City.纽约市社区层面新冠病毒传播的行为驱动预测。
PLoS Comput Biol. 2025 Apr 29;21(4):e1012979. doi: 10.1371/journal.pcbi.1012979. eCollection 2025 Apr.
2
SARS-CoV-2 dynamics in New York City during March 2020-August 2023.2020年3月至2023年8月纽约市的新型冠状病毒2型动态
Commun Med (Lond). 2025 Apr 7;5(1):102. doi: 10.1038/s43856-025-00826-6.
3
Genomic and epidemiological analysis of SARS-CoV-2 variants isolated in Guinea: a routine sequencing implementation.

本文引用的文献

1
Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant.B.1.526新型冠状病毒变异株的流行病学特征。
Sci Adv. 2022 Jan 28;8(4):eabm0300. doi: 10.1126/sciadv.abm0300.
2
Modeling influenza seasonality in the tropics and subtropics.模拟热带和亚热带地区的流感季节性。
PLoS Comput Biol. 2021 Jun 9;17(6):e1009050. doi: 10.1371/journal.pcbi.1009050. eCollection 2021 Jun.
3
A global database of COVID-19 vaccinations.一个全球 COVID-19 疫苗接种数据库。
在几内亚分离出的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的基因组和流行病学分析:一项常规测序实施情况
BMC Infect Dis. 2025 Jan 2;25(1):3. doi: 10.1186/s12879-024-10411-2.
4
Shift in Demographic Involvement and Clinical Characteristics of COVID-19 From Wild-Type SARS-CoV-2 to the Delta Variant in the Indian Population: In Silico Analysis.印度人群中新冠病毒从野生型严重急性呼吸综合征冠状病毒2到德尔塔变异株的人口统计学参与度和临床特征变化:计算机模拟分析
Interact J Med Res. 2024 Oct 8;13:e44492. doi: 10.2196/44492.
5
Reconciling the efficacy and effectiveness of masking on epidemic outcomes.协调口罩对疫情结果的疗效和效果。
J R Soc Interface. 2024 Mar;21(212):20230666. doi: 10.1098/rsif.2023.0666. Epub 2024 Mar 6.
6
Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.预测 SARS-CoV-2 导致的健康结果的模型,包括疫苗接种的效果:系统评价。
Syst Rev. 2024 Jan 16;13(1):30. doi: 10.1186/s13643-023-02411-1.
7
Predicting the spread of SARS-CoV-2 variants: An artificial intelligence enabled early detection.预测新冠病毒变异株的传播:基于人工智能的早期检测
PNAS Nexus. 2024 Jan 2;3(1):pgad424. doi: 10.1093/pnasnexus/pgad424. eCollection 2024 Jan.
8
Isolation may select for earlier and higher peak viral load but shorter duration in SARS-CoV-2 evolution.隔离可能会选择 SARS-CoV-2 进化中更早和更高的峰值病毒载量,但持续时间更短。
Nat Commun. 2023 Nov 21;14(1):7395. doi: 10.1038/s41467-023-43043-2.
9
Impact of vaccinations, boosters and lockdowns on COVID-19 waves in French Polynesia.疫苗接种、加强针和封锁对法属波利尼西亚 COVID-19 浪潮的影响。
Nat Commun. 2023 Nov 13;14(1):7330. doi: 10.1038/s41467-023-43002-x.
10
Development of Accurate Long-lead COVID-19 Forecast.准确的 COVID-19 长期预测的发展。
PLoS Comput Biol. 2023 Jul 17;19(7):e1011278. doi: 10.1371/journal.pcbi.1011278. eCollection 2023 Jul.
Nat Hum Behav. 2021 Jul;5(7):947-953. doi: 10.1038/s41562-021-01122-8. Epub 2021 May 10.
4
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.NVX-CoV2373 新冠疫苗对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5.
5
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.BNT162b2新冠疫苗对B.1.1.7和B.1.351变异株的有效性
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
6
Resurgence of SARS-CoV-2: Detection by community viral surveillance.SARS-CoV-2 再现:社区病毒监测检测。
Science. 2021 May 28;372(6545):990-995. doi: 10.1126/science.abf0874. Epub 2021 Apr 23.
7
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.SARS-CoV-2 变体 B.1.351 和 P.1 逃避中和抗体。
Cell. 2021 Apr 29;184(9):2384-2393.e12. doi: 10.1016/j.cell.2021.03.036. Epub 2021 Mar 20.
8
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.传染性 SARS-CoV-2 B.1.1.7 和 B.1.351 变体对中和抗体的敏感性。
Nat Med. 2021 May;27(5):917-924. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.
9
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.多种 SARS-CoV-2 变异株逃避疫苗诱导的体液免疫中和作用。
Cell. 2021 Apr 29;184(9):2372-2383.e9. doi: 10.1016/j.cell.2021.03.013. Epub 2021 Mar 12.
10
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.SARS-CoV-2 变体 B.1.351 从自然和疫苗诱导的血清中逃逸的证据。
Cell. 2021 Apr 29;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.